Clinical Trials
7 trialsNCT07260175 2026-06-04
adIVO
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Recruiting
NCT07548710 2026-06-03
Study of SA+X in the Treatment of Newly Diagnosed AML
Ruijin Hospital
Phase 2 Recruiting
NCT04250051 2026-06-01
Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia
Northwestern University
Phase 1 Terminated
NCT07607418 2026-05-26
Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS
Ruijin Hospital
Phase 2 Recruiting
NCT04493164 2026-05-22
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04774393 2026-05-20
Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT05615818 2026-05-19
SAFIR-ABC10
UNICANCER
Phase 3 Recruiting